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192 The Journal of Thoracic and CardioObjective: Heart fatty acid–binding protein is a rapid indicator for assessment of
myocardial damage in cardiac surgery. The purpose of this study was to investigate
the effects of age and ischemic time on the biochemical evidence and clinical
outcomes of myocardial damage in pediatric cardiac surgery.
Methods: A prospective observational cohort study conducted over 2.5 years was
performed in 98 consecutive patients (51 infants and 47 children) undergoing
cardiac surgery for ventricular septal defects. Serial measurements of serum levels
of heart fatty acid–binding protein and the respective areas under the curve were
obtained, with particular reference to age and aortic crossclamp time. Assessment of
clinical outcomes included inotropic support, ventilatory support, and intensive care
unit stay.
Results: There was a linear dependence of the logarithm of age and the logarithm of
heart fatty acid–binding protein release(r  0.737, P  .0001). This logarithm-
logarithm plot showed a power function of age for heart fatty acid–binding protein
release. The exponent and amplitude parameter of the power function was the aortic
crossclamp time. Compared with children, infants had significantly more myocar-
dial damage and worse clinical outcomes, and these factors were related to the aortic
crossclamp time.
Conclusions: The younger the age of patients, the more vulnerable are their
myocardia to injury caused by ischemia during definitive repair of congenital heart
disease. Therefore, perioperative management for pediatric patients after cardiac
surgery should be performed, taking into consideration the dependence of the
myocardial damage on age and ischemic time.
Because of recent advances in surgical technique, myocardial pres-ervation and postoperative care have resulted in complete repair ofmany congenital heart defects in the neonatal period or earlyinfancy. On the other hand, several investigators have reported thatimmature myocardium in the pediatric heart is more vulnerable toinjury than mature myocardium in the adult heart.1-3 Perioperative
myocardial injury is a major determinant of cardiac dysfunction after operations for
congenital heart disease. Therefore, it is very important to detect and to evaluate the
degree of myocardial injury as soon as possible after the operative procedure.
Previously, we reported that heart fatty acid–binding protein (HFABP) is a rapid
marker for assessment of myocardial damage and clinical outcome in pediatric
cardiac surgery.4 HFABP is a small intracellular protein consisting of 132 amino
acid residues and weighing 14.9 kd. It is hydrophilous and abundant in the cyto-
plasm of cardiomyocytes in its free form. Its physiologic role is the transport of
long-chain fatty acids from the cell membrane to their intracellular sites of metab-
olism in the mitochondria, where they enter the citric acid cycle. Because this
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Dprotein features a low-molecular-weight and a cytosolic
localization, it leaks out easily from the injured myocardium
and immediately enters the blood circulation.5,6
In this study we analyzed the severity of myocardial
injury in pediatric cardiac surgery by measuring HFABP
release and assessed the effects of age and ischemic time on
the release of HFABP.
Methods
Patient Population
Only patients who had simple ventricular septal defects (VSDs)
were included in this prospective study protocol to exclude bias in
diagnosis and operative technique. From June 1999 through De-
cember 2001, 98 consecutive patients (51 infants 24 months of
age and 47 children 24 months of age) underwent transatrial
repair of VSD at Kobe Children’s Hospital. This age criterion was
selected from the median age of all patients. Preoperative charac-
teristics are summarized in Table 1. No patients required preop-
erative respiratory or inotropic support. Approval from the local
ethics committee was obtained, as was informed consent from all
participating patients or their guardians.
Operative Procedure
Anesthesia was induced and maintained with fentanyl (50-100
g/kg) and vecuronium bromide. Patients were ventilated with
oxygen, air, and isoflurane, and ventilation was adjusted to main-
tain normocarbia. Cardiopulmonary bypass was instituted with an
ascending aortic cannula, bicaval venous cannulas, and systemic
ventricular venting. Systemic flow was maintained between 2.2
and 2.6 L · min1 · m2, and mean arterial pressure was main-
TABLE 1. Patient characteristics
Infants
(n  51)
Children
(n  47)
Preoperative demographic
characteristics
10 (5–14)* 49 (30–84)
Sex (M/F) 31/20 25/22
Body weight (kg) 6.2 (5.0–8.5)* 14.6 (10.9–20.3)
Qp/Qs 3.0 (2.2–3.7)* 1.8 (1.5–2.3)
RV/LV 0.58 (0.44–0.78) 0.47 (0.33–0.78)
LVEF (%) 70 (66–74) 69 (65–74)
Failure to thrive (%) 60.8* 21.3
Intraoperative clinical
characteristics
CPB time (min) 142 (127–151) 137 (108–154)
AoX time (min) 75 (63–83) 71 (56–85)
Lowest rectal
temperature (°C)
28.0 (27.5–28.7)* 29.6 (28.4–30.3)
Data are presented as medians (interquartile range) or number of obser-
vations. Failure to thrive was defined as a patient body weight less than 2
SDs of the normal body weight. Qp/Qs, Pulmonary/systemic flow ratio;
RV/LV, right ventricular/left ventricular systolic pressure ratio; LVEF, left
ventricular ejection fraction; CPB, cardiopulmonary bypass; AoX, aortic
crossclamp.
*P  .01 versus children.tained between 40 and 60 mm Hg. Mild or moderate systemic
The Journal of Thoracihypothermia was used. After completion of VSD closure through
the right atrium and an aortic declamping, rewarming was insti-
tuted. Cardiopulmonary bypass was discontinued with minimal
inotropic support, and modified ultrafiltration was performed in a
stable hemodynamic state.
Protocol of Myocardial Protection
Myocardial protection was achieved with intermittent cold blood
cardioplegia with topical cardiac cooling in all patients. An initial
dose of 300 mL/m2 body surface area was initially infused into an
aortic root at a pressure of 30 mm Hg to achieve cardiac arrest,
with subsequent doses of 150 mL/m2 body surface area infused
every 20 minutes. In all patients, an additional 300 mL of warm
(35°C) blood cardioplegic solution per square meter of body
surface area was infused into the aortic root just before the aortic
declamping.7 Blood cardioplegic solution4 was made by mixing
hyperkalemic crystalloid solution8 with oxygenated blood in a 1:2
ratio and cooled to 9°C (Table 2). At the start of reperfusion, the
aorta was partially declamped for 3 minutes, and the aortic root
pressure was maintained at less than 30 mm Hg to reduce reper-
fusion injury. The aorta was then fully declamped. If ventricular
fibrillation persisted beyond a few minutes after the aortic
declamping, electrical defibrillation was applied to restore normal
sinus rhythm.
Blood Samples and Biochemical Analysis
As markers of myocardial damage, serum concentrations of
HFABP were measured at 6 points during the study protocol as
follows: after induction of anesthesia and before skin incision and
0, 1, 2, 3, and 6 hours after the aortic declamping. Total release of
HFABP was expressed as the area under the curve (AUC) of data
monitored over time. All blood samples were collected through a
radial arterial line and centrifuged immediately. The plasma was
frozen and stored until biochemical analysis was performed. The
serum HFABP level was measured by using a sandwich enzyme-
linked immunosorbent assay with 2 distinct murine anti-HFABP
monoclonal antibodies (Markit-M H-FABP; Dainippon Pharma-
ceutical Co Ltd, Osaka, Japan).9
Assessment of Clinical Outcome
The relationship between serum peak levels of HFABP and intra-
operative and postoperative clinical variables was evaluated. In-
traoperative variables included duration of cardiopulmonary by-
pass, aortic crossclamp (AoX) time, and lower rectal temperature.
TABLE 2. Composition of blood cardioplegia
Na (mmol/L) 97.7 1.2
K (mmol/L) 18.7 0.3
Cl (mmol/L) 90.4 0.8
Mg2 (mmol/L) 1.0 0.01
Ca2 (mmol/L) 0.73 0.01
pH 7.51 0.01
HCO3
 (mmol/L) 17.4 0.3
Hematocrit (%) 18.6 0.6
Osmolarity (mOsm/L) 339 3.1
All data are shown as means  SEM for each composition.Postoperative variables included inotropic score, duration of intu-
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follows: the sum of doses of dopamine (in micrograms per kilo-
gram per minute), dobutamine (in micrograms per kilogram per
minute), and epinephrine (in micrograms per kilogram per minute
 100) multiplied by the number of hours that each drug was
used.10
Statistical Analysis
Database management and statistical analysis were performed with
the Statview (version 5.0) software package (Abacus Concepts
Inc). Normally distributed data are reported as means SEM; data
that were not normally distributed are reported as medians with
interquartile ranges. The methods of analysis included Mann-
Whitney U tests for continuous variables and 2 tests for dichot-
omous parameters. The relationships between preoperative patient
characteristics and preoperative serum HFABP levels and serum
peak HFABP levels were analyzed with forward stepwise regres-
sion. Spearman rank correlation coefficients (2-tailed) were used to
evaluate whether serum peak HFABP levels were correlated with
operative clinical variables. HFABP-AUC and age showed some
degree of positive skewness, and we therefore performed statistical
analysis on the basis of logarithmic transformation of these vari-
ables to get an approximately normal distribution. Linear or non-
linear regression analysis was performed to determine the relation-
ship between HFABP-AUC and age. For this analysis, the age data
were evaluated as continuous variables. In addition, to quantify the
independent effects of age and ischemic time and to examine their
interactive effect, we used a general linear regression model.11
Results
Clinical Outcome
In the forward stepwise multiple regression analysis for all
patients, there was no statistical correlation between preop-
erative patient characteristics and preoperative serum
HFABP levels. Although age, body weight, preoperative
pulmonary/systemic flow ratio (Qp/Qs), and failure to thrive
in infants were significantly different from those in children
(Table 1), preoperative Qp/Qs and failure to thrive did not
correlate with serum peak HFABP levels after aortic
declamping in the forward stepwise multiple regression.
There was no statistical difference between infants and
children regarding cardiopulmonary bypass and AoX time.
No hospital deaths or major postoperative complications
TABLE 3. Clinical outcomes and their correlations with se
Infants
r Value
Inotropic score* 460 (304–959)† 0.755
Intubation time (h) 24 (16–92)† 0.460
ICU stay (d) 6 (3–8)† 0.543
Data are presented as medians (interquartile range). ICU, Intensive care
*Inotropic score is defined as the sum of doses of dopamine (in microgram
and epinephrine (in micrograms per kilogram per minute  100) multipliewere recorded in this study. Transient electrocardiographic
194 The Journal of Thoracic and Cardiovascular Surgery ● Januabnormalities of minor ST-segment changes were observed
in 20 patients but did not relate to the increase in serum
levels of biochemical markers. The postoperative clinical
data are shown in Table 3. Inotropic support was required
with dopamine (range, 2-10 g · kg1 · min1) in all
patients, dobutamine (range, 2-10 g · kg1 · min1) in 46
patients, or epinephrine (range, 0.03-0.1 g · kg1 · min1)
in 2 patients. All postoperative clinical variables were sig-
nificantly better for children than for infants. In both infants
and children, there was a good correlation between serum
peak HFABP levels and inotropic score, with Spearman
rank correlation coefficients of greater than 0.50 (P  .01
for each). Moreover, serum peak HFABP levels in infants
correlated significantly with intubation time and intensive
care unit stay.
Serial Changes in HFABP Levels
Serial changes in HFABP levels are shown in Figure 1.
Before the operation, the baseline of serum HFABP levels
in infants was not different from that in children. Serum
HFABP levels at each point after aortic declamping in
infants were significantly higher than those in children
(median value, 234 vs 97 ng/mL at 0 hour, 455 vs 190
ng/mL at 1 hour, 186 vs 69 ng/mL at 2 hours, 107 vs 41
ng/mL at 3 hours, and 59 vs 22 ng/mL at 6 hours after aortic
declamping, respectively; P  .0001). In both infants and
children, serum HFABP levels reached the peak only 1 hour
after aortic declamping.
Relationship Between Age and HFABP Release
In Figure 2, A, total HFABP release (y), as expressed by the
AUC (HFABP-AUC) and age (x) in pediatric cardiac sur-
gery are plotted on a logarithmic (ln) scale. The straight line
is the least-square regression:
lny  a  blnx (1)
where a  7.97  0.29 and b  0.49  0.09 , with a
correlation coefficient (r) of 0.738. A highly significant
negative correlation was found between the logarithm of
peak HFABP levels
Children
P value r Value P value
.0001 192 (157–260) 0.585 .0001
.0011 9 (6–16) 0.285 .0533
.0001 2 (2–4) 0.180 .2211
kilogram per minute), dobutamine (in micrograms per kilogram per minute),
he number of hours that each drug was used. P  .01 versus children.rum
unit.
s perHFABP release and the logarithm of age (P  .0001). The
ary 2005
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Ddotted lines in Figure 2, A, show the confidence intervals
and prediction limits for the regression lines.
Equation 1 can be rewritten as follows:
y  kxb (2)
where k  exp(a) . Data were back-transformed to get the
usual relationship in the original scale and plotted in Figure
2, B. The solid line in Figure 2, B, denotes equation 2, which
is the nonlinear regression model of the data. It has been
shown that the relationship between HFABP release and age
follows a negatively accelerating power function.
Effect of Age and Ischemic Time on HFABP Release
The 2 subgroups were divided according to AoX time
(group S, 75 minutes; group L, 75 minutes). The crite-
rion of AoX time was selected from the median AoX time
of all patients. Total HFABP release in infants was signif-
icantly greater than that in children (medians of 1133 vs 425
ng/mL, P .0001). The HFABP-AUC level in group L was
higher than that in group S (infants, medians of 1331 vs 873
ng/mL, P  .005; children, medians of 461 vs 368 ng/mL,
P  .011). The HFABP-AUC level was dependent on AoX
time. Moreover, the difference in HFABP release between
the subgroups showed a trend toward a greater increase in
infants than in children (Figure 3). The interaction between
age and AoX time might cause this effect on HFABP
release.
Interaction Between Age and Ischemic Time
Equation 3 represents a fitted general linear regression
model for the logarithm of HFABP release (y), including the
Figure 1. Serum levels of HFABP during the study protocol. Re-
sults are expressed as medians with interquartile ranges. Preop,
Preoperative. *P < .01 versus serum HFABP levels at each point
after aortic declamping in children.logarithm of age (x) as a main variable, AoX time (M) as a
The Journal of Thoracimodifying variable, and the interaction of both variables as
follows:
lny  p  qlnx  rM  slnxM (3)
To estimate the effect of AoX time, M is a dummy
variable defined as follows: M  0 for group S, and M  1
for group L. Table 4 shows the result of this analysis. In the
model of equation 3, as well as equation 1, a highly signif-
icant negative correlation was found between the logarithm
of age and the logarithm of HFABP release (P  .0001).
Also, the logarithm of HFABP release correlated signifi-
cantly with AoX time (P  .0012). There was a significant
negative interaction with age and AoX time (P  .0361).
Equation 3 can be also rewritten as follows:
lny  p  rM  q  sMlnx
y  KxL (4)
where K  exp(p  rM) and L  q  sM. The amplitude
and exponent parameter of this power function was depen-
dent on AoX time. In Figure 4, HFABP-AUC (y) and age
(x) are plotted by AoX time (M). It is clear that the differ-
ence in HFABP release between group S (M  0) and group
L (M  1) showed a greater increase in infants than in
children.
Discussion
Although serum HFABP concentration after cardiac surgery
has only been reported in adult patients,12,13 we recently
found that HFABP is also a rapid indicator for assessment
of myocardial damage in pediatric cardiac surgery. Serum
HFABP levels reached peak level at 1 hour after declamp-
ing, which was significantly earlier than serum creatine
kinase isoenzyme MB or serum cardiac troponin T (TnT)
levels. In addition, serum HFABP levels immediately after
declamping correlated strongly with serum peak HFABP
levels. The serum peak level of HFABP correlated with
those of creatine kinase isoenzyme MB and TnT signifi-
cantly. In multiple regression analysis, age, AoX time, the
presence of a ventriculotomy, and the lowest hematocrit
level during cardiopulmonary bypass were significant intra-
variables that influenced the release of HFABP.4 In this
series serum HFABP levels increased sharply from the
baseline to the peak and reached the peak at 1 hour after
aortic declamping. Ninety-eight percent of our patients
reached their individual peak levels at this time point. These
findings in infants and children agreed with those of the
previous report.
In this study we showed that serum HFABP levels after
pediatric cardiac surgery were significantly influenced by
the age of the patients. It should be emphasized that infants
(24 months of age) displayed significantly greater
amounts of serum HFABP than did children (24 months
c and Cardiovascular Surgery ● Volume 129, Number 1 195
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Dof age) at each time point analyzed. Interestingly, we ob-
served a negative power-law relationship between age and
HFABP release. The validity of this relationship was dem-
onstrated by a highly significant correlation between age
and HFABP release in the ln-ln plot. Previously, Taggart
and colleagues1 have shown that the accumulation of TnT
release shows a power-law relationship to age, as do our
results relative to HFABP release. We can say with fair
certainty that the younger the age of the patients, the more
vulnerable are their myocardia to injury during definitive
repair of congenital heart disease.
Generally, myocardial metabolic response to surgical
stress seems greater in the younger heart. In addition to
HFABP and TnT, Smolenski and coworkers14 reported a
much greater release of lactate, phosphate, and purines in
Figure 2. Relationship between age and HFABP relea
logarithmic scale (A) and nonlinear regression analys
Figure 3. Effect of age and ischemic time on HFABP release.coronary sinus effluent in children aged 2 to 10 years
196 The Journal of Thoracic and Cardiovascular Surgery ● Januundergoing cardiac surgery than in adults. Alcaraz and
associates15 showed that newborn patients displayed signif-
icantly greater amounts of serum interleukin 10 than did
older children in response to cardiac surgery. These findings
support the view that the immaturity or the fine sensibility
of pediatric myocardium results in much more myocardial
metabolic injury and a greater stress response. On the basis
of this view, it is reasonable to postulate that surgical stress
by ischemic time could promote a more biochemical re-
sponse in infants than in children.
Ischemic time was also a highly significant explanatory
variable for the release of HFABP. In both infants and
children, there were positive correlations between ischemic
time and HFABP release. We found that the ischemic time
was the exponent and amplitude parameter of the power
function between age and HFABP release. Interestingly, the
effect of ischemic time on HFABP release was greater in
infants than in children. This fact implied the presence of an
interaction between age and ischemic time. Actually, our
general linear model for HFABP release showed that myo-
cardial damage was dependent on not only age and ischemic
time but also on their interaction. We demonstrated statis-
tically that the heart was more vulnerable to injury caused
by myocardial ischemia in infants than in children.
Postoperative clinical outcomes were related to serum
concentrations of HFABP after aortic declamping. In par-
ticular, we showed that inotropic support correlated signif-
icantly with serum peak HFABP levels in infants and chil-
dren. In our study infants displayed significantly greater
amounts of serum HFABP than did children after cardiac
surgery, and the former had clinical outcomes that were not
esults of linear regression analysis of the data on a
the data in an original scale (B) are shown.se. Ras good as those of children. It is also possible to say that
ary 2005
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on the age of the patient. Recently, definitive repair for
patients with congenital heart disease tends to favor the
younger patients because of the advances in surgical tech-
nique, myocardial preservation, and postoperative care. In
our experience with VSD repair, the mean age of the pa-
tients was 4.4  0.3 years between 1996 and 1998 versus
3.3  0.2 years between 1999 and 2001. The percentage of
patients aged less than 2 years of all patients with VSD
repair was 30.4% between 1996 and 1998 versus 46.1%
between 1999 and 2001. In this tendency it is important to
manage perioperative care for pediatric patients with con-
genital heart disease, taking into consideration the depen-
dence of the myocardial damage on age and ischemic time.
This study population was carefully selected to evaluate
the effects of age and ischemic time on the release of
HFABP in pediatric cardiac surgery. Because of this selec-
tivity, the limitation of the study is an absence of patients
with repair of congenital heart disease, except for a single
VSD. Neonatal patients and patients with cyanosis were not
included in the study. In addition, the analysis was limited
with respect to the presence of large volume overload and
pulmonary hypertension. The severity of VSD is certainly
intensified by pulmonary hypertension, in which case pa-
tients often need surgical repair in infancy rather than in
childhood. Although these factors did not correlate with the
baseline of serum HFABP levels before the operation or
serum peak HFABP levels after aortic declamping, further
studies including the abovementioned patients are intended
to better characterize HFABP in pediatric cardiac surgery.
Another possible limitation is that postoperative clinical
variables can be subjective according to the clinician man-
aging the patient. Clinician bias is, however, unlikely to
have been a confounding factor because the postoperative
management was strictly in accordance with our unit pro-
tocol, and the results were not available to the clinician.
In conclusion, this study expands current knowledge on
myocardial injury in pediatric cardiac surgery and demon-
strates a pattern of HFABP release in infants and children
with dependence on age and ischemic time. Our results
indicated that the younger the age of patients, the more
vulnerable are their myocardia to injury caused by ischemia
during definitive repair of congenital heart disease. There-
TABLE 4. Results of general linear model for the logarithm
Variable Coefficient
Ln (AGE) 0.380
TIME 0.914
Ln (AGE) *TIME 0.185
Intercept 7.446
HFABP, Heart fatty acid– binding protein; CI, confidence interval; Ln, logafore, we should manage perioperative care for pediatric
The Journal of Thoracipatients with congenital heart disease by taking into con-
sideration the dependence of the myocardial damage on age
and ischemic time.
We thank Professor Katsumi Yagi (Department of Mathemat-
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